Notably, the reductions observed in these parameters were greater than those seen with semaglutide 1 mg, another GLP-1 receptor agonist, in the SUPRASS-2 trial.Tirzepatide was generally well-tolerated, with a low risk of hypoglycaemia when used without insulin or insulin secretagogues
Han X, Lu Y, Xu Z, Chu Y, Ma X, Wu H, et al
#iHeardSTL #GLP1 #WeightLossDrugs
Betadine test to check the glow on glutathione soap effectiveness
Summary and Recommendations Based on the studies of antioxidant and mucolytics, various respiratory associations and bodies have made the following recommendations: GOLD Executive Summary 2017 44 : Regular treatment with mucolytics such as carbocysteine and N-acetylcysteine may reduce exacerbations and modestly improve health status in patients not receiving inhaled corticosteroids. European Respiratory Society/American Thoracic Society 2017 84 : In COPD with moderate or severe airflow obstruction and exacerbations despite optimal inhaled therapy, we suggest treatment with an oral mucolytic agent to prevent future exacerbations
How is KLOW different from GLOW or the Wolverine stack